Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Enliven Therapeutics (ELVN)
NASDAQ:ELVN
Enliven Therapeutics (ELVN) Stock Price & Analysis
264 Followers
ELVN Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$9.80 - $26.00
Previous Close$23.87
Volume395.85K
Average Volume (3M)300.89K
Market Cap
$1.12B
Enterprise Value$858.54M
Total Cash (Recent Filing)$263.48M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)-10.9
Beta0.90
Next Earnings
Aug 08, 2024EPS Estimate
-$0.55Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.18
Shares Outstanding41,347,632
10 Day Avg. Volume329,238
30 Day Avg. Volume300,892
Standard Deviation0.30
R-Squared0.03
Alpha-0.00664
Financial Highlights & Ratios
Price to Book (P/B)3.87
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-15.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-22.45
Forecast
1Y Price Target
$36.00Price Target Upside50.00% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Enliven Therapeutics News
Bulls Say, Bears Say
Bulls Say
Drug Development ProgressELVN-001 has demonstrated improved kinome selectivity, tolerability, and robust tumor inhibition versus current leading drugs.
Financial StabilityCash reserves are expected to support ELVN's operations well into the future, allowing continued development of its drug pipeline.
Market PotentialELVN-002 is progressing in clinical trials, targeting HER2 dependent solid tumors with potential treatment for areas of great unmet need.
Bears Say
Analyst CredibilityMizuho Securities may have a conflict of interest that could affect the objectivity of this report.
EarningsELVN reported a Q4 net loss of $19MM.
Short InterestShort Interest (% Float) is high at 20.5%, indicating that a significant portion of the company's tradable shares are being shorted.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ELVN FAQ
What was Enliven Therapeutics’s price range in the past 12 months?
Enliven Therapeutics lowest stock price was $9.80 and its highest was $26.00 in the past 12 months.
What is Enliven Therapeutics’s market cap?
Currently, no data Available
When is Enliven Therapeutics’s upcoming earnings report date?
Enliven Therapeutics’s upcoming earnings report date is Aug 08, 2024 which is in 84 days.
How were Enliven Therapeutics’s earnings last quarter?
Enliven Therapeutics released its earnings results on May 14, 2024. The company reported -$0.54 earnings per share for the quarter, beating the consensus estimate of -$0.543 by $0.003.
Is Enliven Therapeutics overvalued?
According to Wall Street analysts Enliven Therapeutics’s price is currently Undervalued.
Does Enliven Therapeutics pay dividends?
Enliven Therapeutics does not currently pay dividends.
What is Enliven Therapeutics’s EPS estimate?
Enliven Therapeutics’s EPS estimate is -$0.55.
How many shares outstanding does Enliven Therapeutics have?
Enliven Therapeutics has 47,005,447 shares outstanding.
What happened to Enliven Therapeutics’s price movement after its last earnings report?
Enliven Therapeutics reported an EPS of -$0.54 in its last earnings report, beating expectations of -$0.543. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Enliven Therapeutics?
Among the largest hedge funds holding Enliven Therapeutics’s share is Fairmount Funds Management Llc. It holds Enliven Therapeutics’s shares valued at 29M.
---
Enliven Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$36.00 (50.00% Upside)
$36.00 (50.00% Upside)
Blogger Sentiment
Bullish
ELVN Sentiment 100%
Sector Average 70%
Sector Average 70%
Insider Transactions
Sold Shares
Worth $12.3M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
23.04%
12-Months-Change
Fundamentals
Return on Equity
-42.60%
Trailing 12-Months
Asset Growth
195.64%
Trailing 12-Months
Company Description
Enliven Therapeutics
Imara Inc is a clinical-stage biopharmaceutical company engaged in developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of haemoglobin.
---
ELVN Stock 12 Month Forecast
Average Price Target
$36.00
▲(50.00% Upside)
Technical Analysis
Arrowhead Pharmaceuticals
―
Alnylam Pharma
―
Ionis Pharmaceuticals
―
Sarepta Therapeutics
―
Best Analysts Covering ELVN
1 Year
1 Year Success Rate
7/8 ratings generated profit
1 Year Average Return
+55.56%
reiterated a buy rating yesterday
Copying Sam Slutsky's trades and holding each position for 1 Year would result in 87.50% of your transactions generating a profit, with an average return of +55.56% per trade.
---